Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$26.12 - $34.07 $16,481 - $21,498
-631 Reduced 2.06%
30,048 $1.02 Million
Q1 2024

May 15, 2024

SELL
$26.64 - $40.31 $26,267 - $39,745
-986 Reduced 3.11%
30,679 $1.08 Million
Q4 2023

Feb 13, 2024

BUY
$19.95 - $31.0 $3,112 - $4,836
156 Added 0.5%
31,665 $914,000
Q3 2023

Nov 14, 2023

SELL
$21.33 - $59.42 $50,914 - $141,835
-2,387 Reduced 7.04%
31,509 $721,000
Q2 2023

Aug 21, 2023

BUY
$34.33 - $62.11 $195,715 - $354,089
5,701 Added 20.22%
33,896 $1.94 Million
Q1 2023

May 09, 2023

SELL
$26.01 - $48.69 $11,730 - $21,959
-451 Reduced 1.57%
28,195 $1.06 Million
Q4 2022

Feb 14, 2023

BUY
$24.14 - $30.37 $8,931 - $11,236
370 Added 1.31%
28,646 $766,000
Q2 2022

Aug 15, 2022

BUY
$19.74 - $43.01 $67,412 - $146,879
3,415 Added 13.74%
28,276 $614,000
Q1 2022

May 16, 2022

SELL
$36.25 - $52.02 $74,203 - $106,484
-2,047 Reduced 7.61%
24,861 $998,000
Q4 2021

Feb 15, 2022

BUY
$43.27 - $65.72 $38,943 - $59,148
900 Added 3.46%
26,908 $1.28 Million
Q3 2021

Nov 15, 2021

SELL
$53.61 - $67.5 $137,563 - $173,205
-2,566 Reduced 8.98%
26,008 $1.47 Million
Q2 2021

Aug 16, 2021

BUY
$45.13 - $64.99 $344,161 - $495,613
7,626 Added 36.4%
28,574 $1.64 Million
Q4 2020

Feb 16, 2021

BUY
$25.66 - $34.55 $7,672 - $10,330
299 Added 1.45%
20,948 $703,000
Q2 2020

Aug 17, 2020

BUY
$12.65 - $29.57 $55,204 - $129,043
4,364 Added 26.8%
20,649 $559,000
Q1 2020

May 13, 2020

BUY
$10.84 - $20.85 $95,131 - $182,979
8,776 Added 116.87%
16,285 $239,000
Q4 2019

Feb 14, 2020

SELL
$13.02 - $19.5 $2,525 - $3,783
-194 Reduced 2.52%
7,509 $129,000
Q3 2019

Nov 15, 2019

BUY
$17.46 - $29.05 $134,494 - $223,772
7,703 New
7,703 $140,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.